Abstract: A power tool chuck includes a body with a central bore extending along an axis and configured to receive a tool bit, a plurality of angled passageways, and a plurality of jaws received in the passageways and moveable between an axially forward and radially inward clamping position and an axially rearward and radially outward retracted position. At least one jaw has a rear end lying in a first plane transverse to the axis. A first key drive member coupled to a tail portion of the body is configured to be engaged by a second key drive member on a power tool output shaft to non-rotationally couple the body to the output shaft. The first key drive has a forward end lying in a second plane transverse to the axis. The second plane is axially forward of the first plane when the jaws are in the retracted position.

Abstract: A power tool is provided including a tool housing including a motor housing and a handle portion extending longitudinally from the motor housing; a battery receptacle disposed at an end of the handle portion opposite the motor housing, the battery receptacle being configured to receive a battery pack; and a brushless DC (BLDC) motor including an electronically-commutated stator assembly and a rotor assembly configured to rotate with respect to the stator assembly, the stator assembly comprising a stator lamination stack sized to be received within the motor housing having a circumference of approximately 140 to approximately 190 mm. The motor produces a maximum power output of at least 1600 watts for driving an output shaft at a maximum torque of at least 30 inch-pounds and a maximum speed of at least 8000 rotations-per-minute.

Abstract: Disclosed are oral anesthetic pharmaceutical compositions comprising: (a) from about 0.02% to about 25% of a pharmaceutically acceptable acid salt of a .beta.-aminopropiophenone, such as dyclonine HCl; (b) from about 0.02% to about 20% of saccharin; and (c) from about 1% to about 99% of a pharmaceutically acceptable oral carrier. Also provided are methods for providing an anesthetic effect in humans or animals which comprises orally administering to said human or animal a safe and effective amount of these pharmaceutical compositions. Also provided is a novel process for the manufacture of anesthetic lozenges containing a .beta.-aminopropiophenone along with saccharin.

Abstract: Disclosed are oral pharmaceutical preparations which comprise a pharmacologically active drug bound to small particles of an ion-exchange resin to provide a drug-resin complex having a drug content above a specified value. The drug-resin complex is subsequently coated with a water-permeable diffusion barrier coating that is insoluble in gastrointestinal fluids thereby providing a controllable sustained release of drug under conditions encountered in the gastrointestinal tract.

Abstract: Disclosed are oral anesthetic pharmaceutical compositions comprising: (a) from about 0.02% to about 25% of a pharmaceutically acceptable acid salt of a .beta.-aminopropiophenone, such as dyclonine HCl; (b) from about 0.02% to about 20% of saccharin; and (c) from about 1% to about 99% of a pharmaceutically acceptable oral carrier. Also provided are methods for providing an anesthetic effect in humans or animals which comprises orally administering to said human or animal a safe and effective amount of these pharmaceutically compositions. Also provided is a novel process for the manufacture of anesthetic lozenges containing a .beta.-aminopropiophenone along with saccharin.

Abstract: Novel pharmaceutical compositions of matter are disclosed for use in eliciting a topical anesthetic and antimicrobial response, preferably for oral health care purposes, said compositions comprising dyclonine hydrochloride and phenol. When used in combination, dyclonine hydrochloride and phenol provide an improved antimicrobial response.

Abstract: Novel pharmaceutical compositions of matter are disclosed for use in eliciting a topical anesthetic and antimicrobial response, preferably for oral health care purposes, said compositions comprising dyclonine hydrochloride and phenol. When used in combination, dyclonine hydrochloride and phenol provide an improved antimicrobial response.